Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
Autore:
Pitt, B; Byington, RP; Furberg, CD; Hunninghake, DB; Mancini, GBJ; Miller, ME; Riley, W;
Indirizzi:
Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 Div Cardiol, Ann Arbor, MI 48109 USA Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA Wake Forest Univ Winston Salem NC USA 27109 , Winston Salem, NC 27109 USA Univ Minnesota Hosp & Clin, Minneapolis, MN 55455 USA Univ Minnesota Hosp & Clin Minneapolis MN USA 55455 eapolis, MN 55455 USA Univ British Columbia, Vancouver, BC V5Z 1M9, Canada Univ British Columbia Vancouver BC Canada V5Z 1M9 ver, BC V5Z 1M9, Canada
Titolo Testata:
CIRCULATION
fascicolo: 13, volume: 102, anno: 2000,
pagine: 1503 - 1510
SICI:
0009-7322(20000926)102:13<1503:EOAOTP>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; CALCIUM-ANTAGONISTS; TRIAL; RISK; PRAVASTATIN;
Keywords:
amlodipine; atherosclerosis; angiography; ultrasonics; trials; angina; revascularization;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Pitt, B Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, 1500 E MedCtr Dr,3910 Taubman Ctr, Ann Arbor, MI 48109 USA Univ Michigan 1500 E Med Ctr Dr,3910 Taubman Ctr Ann Arbor MI USA 48109
Citazione:
B. Pitt et al., "Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events", CIRCULATION, 102(13), 2000, pp. 1503-1510

Abstract

Background-The results of angiographic studies have suggested that calciumchannel-blocking agents may prevent new coronary lesion formation, the progression of minimal lesions, or both. Methods and Results-The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was a multicenter, randomized, placebo-controlled, double-masked clinical trial designed to test whether amlodipinewould slow the progression of early coronary atherosclerosis in 825 patients with angiographically documented coronary artery disease. The primary outcome was the average 36-month angiographic change in mean minimal diameters of segments with a baseline diameter stenosis of 30%. A secondary hypothesis was whether amlodipine would reduce the rate of atherosclerosis in the carotid arteries as assessed with B-mode ultrasonography, which measured intimal-medial thicknesses (IMT). The rates of clinical events were also monitored. The placebo and amlodipine groups had nearly identical average 36-month reductions in the minimal diameter: 0.084 versus 0.095 mm, respectively(P=0.38). In contrast, amlodipine had a significant effect in slowing the 36-month progression of carotid artery atherosclerosis: the placebo group experienced a 0.033-mm increase in IMT, whereas there was a 0.0126-mm decrease in the amlodipine group (P=0.007). There was no treatment difference in the rates of all-cause mortality or major cardiovascular events, although amlodipine use was associated with fewer cases of unstable angina and coronary revascularization. Conclusions-Amlodipine has no demonstrable effect on angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but is associated with fewer hospitalizations for unstable angina and revascularization.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 04:27:10